Take­da takes a swing at RNA small mol­e­cules with dis­cov­ery pact for mul­ti­ple po­ten­tial Evotec pro­grams

5 years ago
Deals
R&D

Covid-19 roundup: Dai­ichi's mR­NA shot en­ters the clin­ic; South Africa sells its As­traZeneca sup­ply to neigh­bors

5 years ago
Coronavirus

Pfiz­er has run 41 tri­als over 15 years for tanezum­ab. As ad­comm nears, the FDA re­mains unim­pressed — and more than ...

5 years ago
Pharma
FDA+

In­no­force gets $96M to build up Chi­na cam­pus, in­clud­ing a new Ther­mo Fish­er-part­nered mon­o­clon­al an­ti­body ...

5 years ago
Cell/Gene Tx
Manufacturing

Those NDA plans Odonate had for mid-'21? They're be­ing scrapped — along with the en­tire biotech — in a sud­den ...

5 years ago
R&D

PhRMA at­tacks New Mex­i­co’s ‘short on de­tail’ plan for Cana­di­an drug im­ports

5 years ago
Pharma
FDA+

Xy­lo­Cor finds new back­ing to push re­gen­er­a­tive heart dis­ease gene ther­a­py deep­er in­to the clin­ic

5 years ago
Financing
Cell/Gene Tx

Roche claims key win in the $12B ear­ly-stage check­point race

5 years ago
R&D
Pharma

As­traZeneca read­ies April EUA fil­ing with 79% vac­cine ef­fi­ca­cy, first glimpse of el­der­ly da­ta and 100% pro­tec­tion ...

5 years ago
R&D
Coronavirus

José Basel­ga, ac­claimed drug hunter, physi­cian and As­traZeneca's pi­o­neer­ing can­cer R&D chief, has died

5 years ago
People

Bridge­Bio team clears a key hur­dle with their proof-of-con­cept da­ta for a rare ge­net­ic dis­ease. And they can thank ...

5 years ago
R&D

Mer­ck­'s C-suite shake­up, Eli Lil­ly stirs fresh Alzheimer's con­tro­very, play by play of Am­gen's $2B buy­out, and more

5 years ago
Weekly

FDA ac­cepts Bris­tol My­er­s' pitch for for­mer MyoKar­dia drug; Clo­vis' Rubra­ca aces ad­vanced ovar­i­an can­cer study

5 years ago
News Briefing

A packed MS mar­ket is about to get busier as J&J's pones­i­mod en­ters the fray

5 years ago
Pharma
FDA+

Kiniksa touts 3rd ap­proval for ag­ing Ar­c­a­lyst — a good haul for just $5M in cash it paid Re­gen­eron for the drug

5 years ago
FDA+

The Ides of March bring no mis­for­tune to biotech, as in­dus­try logs sec­ond-busiest IPO week of 2021

5 years ago
Financing

UK drug reg­u­la­tor to restart in­spec­tions at the end of March with a fo­cus on so­cial dis­tanc­ing

5 years ago
FDA+
Coronavirus

Gone away are the blue­bird ex­ecs as COO, CMO both leave the nest; Mike Nal­ly is lat­est ma­jor fig­ure to move on from ...

5 years ago
Peer Review

Mer­ck breathes a sigh of re­lief as Keytru­da-Lenvi­ma com­bo aces con­fir­ma­to­ry study in en­dome­tri­al can­cer

5 years ago
R&D
Pharma

FDA spells out how the Covid-19 vari­ants im­pact the ef­fec­tive­ness of Re­gen­eron, Eli Lil­ly mAb treat­ments

5 years ago
FDA+
Coronavirus

Out­bid­ding 14 oth­ers and then them­selves: How Am­gen spent $2 bil­lion on a biotech that had been on the brink

5 years ago
Deals

Founders of poop-test­ing uBio­me, re­port­ed­ly on the run, charged by SEC with de­fraud­ing in­vestors

5 years ago
People

Christo­pher Austin makes his re­turn to in­dus­try, jump­ing ship from NIH over to CEO-part­ner role at Flag­ship

5 years ago
People

Jakafi failed the pri­ma­ry end­point in a Covid-19 study. But In­cyte is still go­ing to FDA with a com­pas­sion­ate use ...

5 years ago
R&D
Coronavirus
First page Previous page 719720721722723724725 Next page Last page
A service from the Financial Times